Chen-Hsuan Lin

Chen-Hsuan Lin

Auto-generated profile, based on publicly available information

Chen-Hsuan Lin

School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2025 in Journal of Infection and Public Health
Verified
Journal Article
Open access
LLLi-Teh Liu
Li-Teh Liu
PCPo-Chih Chen
Po-Chih Chen
CLChen-Hsuan Lin
Chen-Hsuan Lin
SHShi-Ya Huang
Shi-Ya Huang
CCChun-Hong Chen
Chun-Hong Chen
JTJih-Jin Tsai
Jih-Jin Tsai
Dengue virus (DENV) is a mosquito-borne flavivirus that remains a global public health threat, particularly in tropical regions where it is endemic. Accurate and timely diagnosis is critical for optimal patient care and effective outbreak containment. While reverse transcription-polymerase chain reaction (RT-PCR) remains the gold standard for dengue diagnosis, nonstructural protein 1 (NS1) rapid diagnostic tests (RDTs) offer a more accessible alternative. However, their performance may vary with infection type, serotype, and the timing of sample collection. We evaluated the diagnostic performance of two NS1 RDTs, Abbott NS1 and PBF NS1, against RT-PCR as the reference standard. A total of 183 dengue-positive and 40 dengue-negative samples were obtained during the 2023 dengue outbreak in Kaohsiung, Taiwan. Sensitivity, specificity, and predictive values were comprehensively assessed based on infection type, serotype, and post-symptom onset (PSO) intervals. Additionally, we analyzed the diagnostic benefits of combining NS1 detection with anti-DENV IgM serology. Abbott NS1 exhibited notably higher sensitivity (87.4 % vs. 83.1 %) and specificity (100 % vs. 97.5 %) compared to PBF NS1, though the differences were not statistically significant. Sensitivity varied by PSO, with Abbott NS1 achieving significantly higher sensitivity beyond three days (97.4 % vs. 76.9 %, P = 0.034). In secondary infections, Abbott NS1 outperformed PBF NS1 (86.8 % vs. 79.2 %). When combined with anti-DENV IgM serology, both RDTs demonstrated improved diagnostic sensitivity, particularly in secondary infections. Our findings underscore the importance of context-specific diagnostic tools. Combining NS1 antigen detection with IgM serology enhances diagnostic accuracy. While Abbott NS1 demonstrated slightly better performance, PBF NS1 remains a viable and non-inferior alternative.

29 November 2025 in Journal of Infection and Public Health
Verified
Journal Article
Open access
LLLi-Teh Liu
Li-Teh Liu
CCChao-Ju Chen
Chao-Ju Chen
PCPo-Chih Chen
Po-Chih Chen
CCChun-Hong Chen
Chun-Hong Chen
PLPing-Chang Lin
Ping-Chang Lin
JTJih-Jin Tsai
Jih-Jin Tsai
The continued evolution of SARS-CoV-2 Omicron sublineages requires ongoing genomic and epidemiological surveillance. This study investigated the genomic epidemiology, national trends, and clinical aspects of SARS-CoV-2 in Taiwan from November 2023 to February 2025. We analyzed the molecular and clinical characteristics of a local cohort (n = 22) from southern Taiwan. Case and mortality trends were evaluated using nationwide surveillance data, considering changes in case definitions. Broader genomic surveillance included 1782 Taiwanese sequences from GISAID to characterize the distribution and evolution of Omicron subvariants, considering the rollout timeline of XBB.1.5 and JN.1 vaccines. Genomic surveillance revealed a major epidemiological shift driven by variant succession: JN.1 and its descendants (e.g., KP.2, KP.3) replaced XBB-related subvariants, coinciding with infection waves in early and mid-2024. A more stringent national case definition for "severe complicated COVID-19" implemented in September 2024, substantially altered epidemiological metrics, reducing reported cases but increasing case fatality. In the local cohort, no significant associations were observed between sex, age, Ct value, comorbidity number, or vaccination status and hospitalization or severity, likely due to limited sample size. Nationally, individuals aged ≥ 65 years were disproportionately represented among severe cases and deaths, with risk amplified in those with comorbidities and low recent XBB.1.5/JN.1 vaccination coverage. Taiwan experienced dynamic evolution of SARS-CoV-2 Omicron, dominated by JN.1 and its derivatives, which drove successive infection waves. Changes in national case definitions created substantial surveillance artifacts complicating interpretation of disease burden. Although national data reaffirm advanced age as the key risk factor for severe outcomes, these findings underscore the importance of targeted vaccination strategies and integrated surveillance systems capable of distinguishing the effects of viral evolution from policy-driven reporting changes.

5 August 2026 in International Journal of Rheumatic Diseases
Verified
Journal Article
Open access
CYChang‐Yi Yen
Chang‐Yi Yen
CLChang‐Chi Lin
Chang‐Chi Lin
PLPing‐Chang Lin
Ping‐Chang Lin
CTChing‐Yi Tsai
Ching‐Yi Tsai
LLLi-Teh Liu
Li-Teh Liu
Jeng-Hsien YenJeng-Hsien Yen
Jeng-Hsien Yen
Objectives: Chikungunya virus (CHIKV) infection might cause chronic chikungunya arthritis resembling rheumatoid arthritis (RA). The purpose of this study is to investigate the potential role of this virus in the pathogenesis of RA in Taiwan, a non‐endemic area. Methods: This cross‐sectional study enrolled 98 RA patients and 200 healthy controls. Serum CHIKV IgM and IgG were tested using two commercial enzyme‐linked immunosorbent assay (ELISA) kits (Abcam and Euroimmun) and an in‐house neutralization assay. ELISA‐IgM was performed only in patients with RA. ELISA or neutralization positive samples were further tested for CHIKV RNA by reverse‐transcription‐polymerase chain reaction. Associations between CHIKV seropositivity and various autoantibodies were analyzed. The agreements among these assays were also evaluated. Results: Neutralizing antibodies were detected in 2 of 98 RA patients and in none of the controls ( p = 0.107, Fisher's exact test; p = 0.043, chi‐square). Both patients were absent from Abcam‐IgM and ‐IgG, as well as Euroimmun‐IgM and ‐IgG testing. There was no association between Abcam‐IgM or Euroimmun‐IgM and rheumatoid factor, anti‐cyclic citrullinated peptide, antinuclear, or anti‐extractable nuclear antigen antibodies. Poor agreements were noted between the neutralizing assay and Abcam‐IgG or Euroimmun‐IgG ( κ = 0 and 0, respectively). A similar finding was also found between Abcam‐IgM and Euroimmun‐IgM ( κ = −0.38). Conclusion: Our study was not sufficiently powered to establish a causal association between CHIKV infection and RA development. Poor agreements were noted among different commercial ELISA kits and neutralization assays, underscoring the limitations of the serology assay.